NetworkNewsBreaks – Imagin Medical Inc. (CSE: IM
Post# of 31
(Total Views: 94)
Posted On: 08/27/2021 4:28:48 PM
NetworkNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Closes on $3M Convertible Note
Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures, announced that it had secured a new convertible note totaling $3 million. Financing for the note, which was comprised of three tranches, was led by Rapha Capital BioVentures Fund I, LP (“RCBVFI”). The company anticipates using the funds to support the clinical development of its lead product, the i/Blue(TM) Imaging System. According to the company, the proprietary system is poised to increase patient access to this important technology. In addition to the funding, Imagin Medical also named Kevin Slawin, MD, a leading uro oncologist and manager of RCBVFI, as a new board member. Slawin has cared for patients with cancer for more than 25 years and brings with him a deep knowledge of the field and of the needs of patients with prostate and bladder cancer. According to the announcement, Slawin noted that taking the lead investor role in Imagin signifies his appreciation of Imagin’s advanced technology and the potential it may bring to the improvement in the care of these patients. Finally the company also unveiled a new enhanced website, which features its new logo and reflects the change in energy and direction of Imagin Medical. “We are excited to bring Dr. Slawin onto the leadership team as a board member at Imagin Medical,” said Imagin Medical president and CEO Jim Hutchens in the press release. “This additional funding will support the company’s progress in bringing our lead product, the i/Blue(TM) Imaging System, through the FDA submission process over the next year.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures, announced that it had secured a new convertible note totaling $3 million. Financing for the note, which was comprised of three tranches, was led by Rapha Capital BioVentures Fund I, LP (“RCBVFI”). The company anticipates using the funds to support the clinical development of its lead product, the i/Blue(TM) Imaging System. According to the company, the proprietary system is poised to increase patient access to this important technology. In addition to the funding, Imagin Medical also named Kevin Slawin, MD, a leading uro oncologist and manager of RCBVFI, as a new board member. Slawin has cared for patients with cancer for more than 25 years and brings with him a deep knowledge of the field and of the needs of patients with prostate and bladder cancer. According to the announcement, Slawin noted that taking the lead investor role in Imagin signifies his appreciation of Imagin’s advanced technology and the potential it may bring to the improvement in the care of these patients. Finally the company also unveiled a new enhanced website, which features its new logo and reflects the change in energy and direction of Imagin Medical. “We are excited to bring Dr. Slawin onto the leadership team as a board member at Imagin Medical,” said Imagin Medical president and CEO Jim Hutchens in the press release. “This additional funding will support the company’s progress in bringing our lead product, the i/Blue(TM) Imaging System, through the FDA submission process over the next year.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)